Journal of Gastrointestinal Cancer

, Volume 48, Issue 3, pp 241–245 | Cite as

Cancer Stem Cells in Hepatocellular Carcinoma

  • Tamer YagciEmail author
  • Metin Cetin
  • Pelin Balcik Ercin
Review Article



Hepatocellular carcinoma is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Only a small proportion of patients benefit from curative treatment and the prognosis is very poor for the majority of cases due to late presentation, resistance to chemotherapy and high recurrence rate. In recent years, progress in stem cell biology allowed us to explain that hierarchically organized cancer stem cells (CSCs) drive histological and functional heterogeneity of hematological malignancies and solid tumors.

Methods and Results

Also referred to as tumor-initiating cells, CSCs have been isolated from both hepatocellular carcinoma (HCC) cell lines and primary tumors by using hepatic progenitor markers. Although there is still no consensus on cancer stem cell phenotype in HCC, single or combined use of CSC markers defines a minor population of tumor cells with the capacity of self-renewing and the ability to recapitulate the original tumor heterogeneity.


This review focuses on the biological features of CSCs and their potential as diagnostic/prognostic tools and therapeutic targets in HCC.


Hepatocellular carcinoma Cancer stem cells Cancer stem cell markers Tumor heterogeneity Tumor recurrence Metastasis 



The study was supported by a grant of The Scientific and Technological Research Council of Turkey (TUBITAK) to Tamer Yagci (111S484). The authors apologize to those investigators whose meritorious works were not cited due to space limitations.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Reya T, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Soltysova A, Altanerova V, Altaner C. Cancer stem cells. Neoplasma. 2005;52(6):435.PubMedGoogle Scholar
  4. 4.
    Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717–28.CrossRefPubMedGoogle Scholar
  5. 5.
    Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197(4302):461–3.CrossRefPubMedGoogle Scholar
  6. 6.
    Dick D. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature med. 1997;3(730–737):1.Google Scholar
  7. 7.
    Al-Hajj M, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100(7):3983–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dalerba P, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci. 2007;104(24):10158–63.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    O’Brien CA, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Ricci-Vitiani L, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Li C, et al. Identification of pancreatic cancer stem cells. Cancer res. 2007;67(3):1030–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Singh SK, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.CrossRefPubMedGoogle Scholar
  13. 13.
    Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60.CrossRefPubMedGoogle Scholar
  14. 14.
    Piccirillo S, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444(7120):761–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Chiba T, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties. Hepatology. 2006;44(1):240–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Haraguchi N, et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006;24(3):506–13.CrossRefPubMedGoogle Scholar
  17. 17.
    Yang ZF, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13(2):153–66.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhang S, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer res. 2008;68(11):4311–20.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Curley MD, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27(12):2875–83.PubMedGoogle Scholar
  20. 20.
    Sugihara E, Saya H. Complexity of cancer stem cells. Int J Cancer. 2013;132(6):1249–59.CrossRefPubMedGoogle Scholar
  21. 21.
    Clevers H. The cancer stem cell: premises, promises and challenges. Nat med. 2011:313–9.Google Scholar
  22. 22.
    Zhou B-BS, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat rev Drug Discov. 2009;8(10):806–23.CrossRefPubMedGoogle Scholar
  23. 23.
    Patel P, Chen E. Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol. 2012;3:125.CrossRefGoogle Scholar
  24. 24.
    Mani SA, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741–51.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMedGoogle Scholar
  27. 27.
    London W, McGlynn K. Liver cancer. Cancer Epidemiology and Prevention. 2006;3:763–86.CrossRefGoogle Scholar
  28. 28.
    Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  29. 29.
    Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol. 2010;25(9):1485–92.CrossRefPubMedGoogle Scholar
  30. 30.
    Ma S, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542–56.CrossRefPubMedGoogle Scholar
  31. 31.
    Suetsugu A, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys res Commun. 2006;351(4):820–4.CrossRefPubMedGoogle Scholar
  32. 32.
    Yamashita T, et al. Activation of hepatic stem cell marker EpCAM by Wnt–β-catenin signaling in hepatocellular carcinoma. Cancer res. 2007;67(22):10831–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Turner R, et al. Human hepatic stem cell and maturational liver lineage biology. Hepatology. 2011;53(3):1035–45.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Zhang L, et al. The stem cell niche of human livers: symmetry between development and regeneration. Hepatology. 2008;48(5):1598–607.CrossRefPubMedGoogle Scholar
  35. 35.
    Tang Y, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling. Proc Natl Acad Sci. 2008;105(7):2445–50.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Chen Y, et al. Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture. Hepatology. 2012;55(2):563–74.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Yin S, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444–50.CrossRefPubMedGoogle Scholar
  38. 38.
    Yang ZF, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47(3):919–28.CrossRefPubMedGoogle Scholar
  39. 39.
    Yamashita T, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–1024. e4.CrossRefPubMedGoogle Scholar
  40. 40.
    Haraguchi N, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120(9):3326–39.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Yin AH, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90(12):5002–12.PubMedGoogle Scholar
  42. 42.
    Grosse-Gehling P, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol. 2013;229(3):355–78.CrossRefPubMedGoogle Scholar
  43. 43.
    Zheng Y-W, et al. The CD133+ CD44+ precancerous subpopulation of oval cells is a therapeutic target for hepatocellular carcinoma. Stem Cells dev. 2014;23(18):2237–49.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Tang KH, et al. CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 2012;55(3):807–20.CrossRefPubMedGoogle Scholar
  45. 45.
    Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35(3):211–31.CrossRefPubMedGoogle Scholar
  46. 46.
    Afify A, Purnell P, Nguyen L. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol. 2009;86(2):95–100.CrossRefPubMedGoogle Scholar
  47. 47.
    van der Windt GJ, et al. CD44 is protective during hyperoxia-induced lung injury. Am J Respir Cell Mol Biol. 2011;44(3):377–83.CrossRefPubMedGoogle Scholar
  48. 48.
    Zhu Z, et al. Cancer stem/progenitor cells are highly enriched in CD133+ CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126(9):2067–78.PubMedGoogle Scholar
  49. 49.
    Reif AE, Allen JM. The AKR thymic antigen and its distribution in leukemias and nervous tissues. J Exp med. 1964;120(3):413–33.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Mima K, et al. CD44s regulates the TGF-β–mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer res. 2012;72(13):3414–23.CrossRefPubMedGoogle Scholar
  51. 51.
    Ishimoto T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc− and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400.CrossRefPubMedGoogle Scholar
  52. 52.
    Lu J-W, et al. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem. 2011;113(8):833–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Went PT, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Kim JW, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology. 2004;39(2):518–27.CrossRefPubMedGoogle Scholar
  55. 55.
    Yamashita T, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology. 2013;57(4):1484–97.CrossRefPubMedGoogle Scholar
  56. 56.
    Kurtz J-E, Dufour P. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010;10(6):951–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Gires O, Bauerle PA. EpCAM as a target in cancer therapy. J Clin Oncol. 2010;28(15):e239–40.CrossRefPubMedGoogle Scholar
  58. 58.
    Mina-Osorio P. The moonlighting enzyme CD13: old and new functions to target. Trends Mol med. 2008;14(8):361–71.CrossRefPubMedGoogle Scholar
  59. 59.
    Kim HM, et al. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial–mesenchymal transition-like phenomenon. Ann Surg Oncol. 2012;19(3):539–48.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Molecular Biology and GeneticsGebze Technical UniversityCayirovaTurkey

Personalised recommendations